[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4982 Referred in Senate (RFS)]

<DOC>
114th CONGRESS
  2d Session
                                H. R. 4982


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                              May 12, 2016

     Received; read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 AN ACT


 
To direct the Comptroller General of the United States to evaluate and 
      report on the in-patient and outpatient treatment capacity, 
             availability, and needs of the United States.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Examining Opioid Treatment 
Infrastructure Act of 2016''.

SEC. 2. STUDY ON TREATMENT INFRASTRUCTURE.

    Not later than 24 months after the date of enactment of this Act, 
the Comptroller General of the United States shall initiate an 
evaluation, and submit to Congress a report, of the inpatient and 
outpatient treatment capacity, availability, and needs of the United 
States, which shall include, to the extent data are available--
            (1) the capacity of acute residential or inpatient 
        detoxification programs;
            (2) the capacity of inpatient clinical stabilization 
        programs, transitional residential support services, and 
        residential rehabilitation programs;
            (3) the capacity of demographic specific residential or 
        inpatient treatment programs, such as those designed for 
        pregnant women or adolescents;
            (4) geographical differences of the availability of 
        residential and outpatient treatment and recovery options for 
        substance use disorders across the continuum of care;
            (5) the availability of residential and outpatient 
        treatment programs that offer treatment options based on 
        reliable scientific evidence of efficacy for the treatment of 
        substance use disorders, including the use of Food and Drug 
        Administration-approved medicines and evidence-based 
        nonpharmacological therapies;
            (6) the number of patients in residential and specialty 
        outpatient treatment services for substance use disorders;
            (7) an assessment of the need for residential and 
        outpatient treatment for substance use disorders across the 
        continuum of care;
            (8) the availability of residential and outpatient 
        treatment programs to American Indians and Alaska Natives 
        through an Indian health program (as defined by section 4 of 
        the Indian Health Care Improvement Act (25 U.S.C. 1603)); and
            (9) the barriers (including technological barriers) at the 
        Federal, State, and local levels to real-time reporting of de-
        identified information on drug overdoses and ways to overcome 
        such barriers.

            Passed the House of Representatives May 11, 2016.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.
